Progestogens in Menopausal Hormone Therapy

Overview

Journal Prz Menopauzalny

Publisher Termedia

Date 2015 Sep 2

PMID 26327902

Citations 6

Authors

Malgorzata Binkowska

Jaroslaw Woron

Affiliations

Soon will be listed here.

Abstract

Progestogens share one common effect: the ability to convert proliferative endometrium to its secretory form. In contrast, their biological activity is varied, depending on the chemical structure, pharmacokinetics, receptor affinity and different potency of action. Progestogens are widely used in the treatment of menstrual cycle disturbances, various gynaecological conditions, contraception and menopausal hormone therapy. The administration of progestogen in menopausal hormone therapy is essential in women with an intact uterus to protect against endometrial hyperplasia and cancer. Progestogen selection should be based on the characteristics available for each progestogen type, relying on the assessment of relative potency of action in experimental models and animal models, and on the indirect knowledge brought by studies of the clinical use of different progestogen formulations. The choice of progestogen should involve the conscious use of knowledge of its benefits, with a focus on minimizing potential side effects. Unfortunately, there are no direct clinical studies comparing the metabolic effects of different progestogens.

Citing Articles

The impact of progestogens on RAAS - a systematic review.

Singer A, Tropschuh K, von Gernler M, Decrinis C, Stute P BMC Womens Health. 2025; 25(1):81.

PMID: 39987087 PMC: 11846257. DOI: 10.1186/s12905-025-03587-5.

Immunohistochemical Analysis of GATA2 Expression in Endometrium and its Relationship with Hormone Receptor Expression in Benign and Premalignant Endometrial Disorders.

Keske A, Polaki U, Matson D Reprod Sci. 2024; 31(12):3880-3891.

PMID: 39443360 PMC: 11611599. DOI: 10.1007/s43032-024-01730-5.

Steroids Bearing Heteroatom as Potential Drugs for Medicine.

Dembitsky V Biomedicines. 2023; 11(10).

PMID: 37893072 PMC: 10604304. DOI: 10.3390/biomedicines11102698.

MIG-6 Is Critical for Progesterone Responsiveness in Human Complex Atypical Hyperplasia and Early-Stage Endometrial Cancer.

Jeong O, Broaddus R, Lessey B, Risinger J, Hunter M, Kim T Int J Mol Sci. 2022; 23(23).

PMID: 36498921 PMC: 9738720. DOI: 10.3390/ijms232314596.

Progestogens as a component of menopausal hormone therapy: the right molecule makes the difference.

Stevenson J, Rozenberg S, Maffei S, Egarter C, Stute P, Romer T Drugs Context. 2020; 9.

PMID: 33312219 PMC: 7716720. DOI: 10.7573/dic.2020-10-1.

References

Ruan X, Seeger H, Mueck A . The pharmacology of nomegestrol acetate. Maturitas. 2012; 71(4):345-53. DOI: 10.1016/j.maturitas.2012.01.007. View

Lindgren R, Risberg B, Hammar M, Berg G, PRYSE-DAVIES J . Endometrial effects of transdermal estradiol/norethisterone acetate. Maturitas. 1992; 15(1):71-8. DOI: 10.1016/0378-5122(92)90064-b. View

Shapiro S . Risk of breast cancer among users of estrogen plus progestogen and unopposed estrogen: is the likelihood of bias symmetrical?. Climacteric. 2015; 18(3):333-5. DOI: 10.3109/13697137.2015.1007623. View

Godsland I . Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril. 2001; 75(5):898-915. DOI: 10.1016/s0015-0282(01)01699-5. View

Stevenson J, Panay N, Pexman-Fieth C . Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety. Maturitas. 2013; 76(1):10-21. DOI: 10.1016/j.maturitas.2013.05.018. View

Canonico M, Fournier A, Carcaillon L, Olie V, Plu-Bureau G, Oger E . Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol. 2009; 30(2):340-5. DOI: 10.1161/ATVBAHA.109.196022. View

Rossouw J, Prentice R, Manson J, Wu L, Barad D, Barnabei V . Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297(13):1465-77. DOI: 10.1001/jama.297.13.1465. View

Caruso S, Serra A, Grillo C, De Leo V, Maiolino L, Agnello C . Prospective study evaluating olfactometric and rhinomanometric outcomes in postmenopausal women on 1 mg 17beta-estradiol and 2 mg drospirenone HT. Menopause. 2008; 15(5):967-72. DOI: 10.1097/gme.0b013e31816be973. View

White W, Hanes V, Mallareddy M, Chauhan V . Effects of the hormone therapy, drospirenone and 17-beta estradiol, on early morning blood pressure in postmenopausal women with hypertension. J Am Soc Hypertens. 2010; 2(1):20-7. DOI: 10.1016/j.jash.2007.08.004. View

10.

Boyd R, Zegarac E, Eldon M . The effect of food on the bioavailability of norethindrone and ethinyl estradiol from norethindrone acetate/ethinyl estradiol tablets intended for continuous hormone replacement therapy. J Clin Pharmacol. 2003; 43(1):52-8. DOI: 10.1177/0091270002239706. View

11.

Stein D, Wright D . Progesterone in the clinical treatment of acute traumatic brain injury. Expert Opin Investig Drugs. 2010; 19(7):847-57. DOI: 10.1517/13543784.2010.489549. View

12.

Stevenson J, Durand G, Kahler E, Pertynski T . Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study. Maturitas. 2010; 67(3):227-32. DOI: 10.1016/j.maturitas.2010.07.002. View

13.

Bray P, Larson J, LaCroix A, Manson J, Limacher M, Rossouw J . Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. Am J Cardiol. 2008; 101(11):1599-1605. PMC: 3543778. DOI: 10.1016/j.amjcard.2008.01.043. View

14.

Hiroi M, Stanczyk F, Goebelsmann U, Brenner P, Lumkin M, Mishell Jr D . Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration. Steroids. 1975; 26(3):373-86. DOI: 10.1016/0039-128x(75)90082-3. View

15.

Schindler A, Campagnoli C, Druckmann R, Huber J, Pasqualini J, Schweppe K . Classification and pharmacology of progestins. Maturitas. 2003; 46 Suppl 1:S7-S16. DOI: 10.1016/j.maturitas.2003.09.014. View

16.

Stanczyk F . Treatment of postmenopausal women with topical progesterone creams and gels: are they effective?. Climacteric. 2014; 17 Suppl 2:8-11. DOI: 10.3109/13697137.2014.944496. View

17.

Anderson G, Limacher M, Assaf A, Bassford T, Beresford S, Black H . Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004; 291(14):1701-12. DOI: 10.1001/jama.291.14.1701. View

18.

Kaya C, Cengiz S, Cengiz B, Akgun G . Long-term effects of low-dose 17beta-estradiol plus dydrogesterone on 24-h ambulatory blood pressure in healthy postmenopausal women: a 1-year, randomized, prospective study. Gynecol Endocrinol. 2007; 23 Suppl 1:62-7. DOI: 10.1080/09513590701584956. View

19.

Calle E, Feigelson H, Hildebrand J, Teras L, Thun M, Rodriguez C . Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. Cancer. 2009; 115(5):936-45. DOI: 10.1002/cncr.24101. View

20.

Salpeter S, Walsh J, Ormiston T, Greyber E, Buckley N, Salpeter E . Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006; 8(5):538-54. DOI: 10.1111/j.1463-1326.2005.00545.x. View